Last reviewed · How we verify

Zydelig

University of Maryland, Baltimore · FDA-approved active Small molecule

Zydelig is a Small molecule drug developed by University of Maryland, Baltimore. It is currently FDA-approved for Chronic lymphoid leukemia, disease, Follicular non-Hodgkin's lymphoma, Malignant lymphoma - small lymphocytic. Also known as: Idelalisib.

At a glance

Generic nameZydelig
Also known asIdelalisib
SponsorUniversity of Maryland, Baltimore
TargetDNA-dependent protein kinase catalytic subunit, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Approved indications

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Zydelig

What is Zydelig?

Zydelig is a Small molecule drug developed by University of Maryland, Baltimore, indicated for Chronic lymphoid leukemia, disease, Follicular non-Hodgkin's lymphoma, Malignant lymphoma - small lymphocytic.

What is Zydelig used for?

Zydelig is indicated for Chronic lymphoid leukemia, disease, Follicular non-Hodgkin's lymphoma, Malignant lymphoma - small lymphocytic.

Who makes Zydelig?

Zydelig is developed and marketed by University of Maryland, Baltimore (see full University of Maryland, Baltimore pipeline at /company/university-of-maryland-baltimore).

Is Zydelig also known as anything else?

Zydelig is also known as Idelalisib.

What development phase is Zydelig in?

Zydelig is FDA-approved (marketed).

What are the side effects of Zydelig?

Common side effects of Zydelig include Diarrhea, Pneumonia, Pyrexia, Fatigue, Rash, Cough. Serious adverse events: Pneumonia, Diarrhea, Pyrexia, Sepsis.

What does Zydelig target?

Zydelig targets DNA-dependent protein kinase catalytic subunit, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform.

Related